- Trials with a EudraCT protocol (89)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
89 result(s) found for: Autoantibody.
Displaying page 1 of 5.
EudraCT Number: 2012-000385-38 | Sponsor Protocol Number: BEL116472 | Start Date*: 2012-05-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy | |||||||||||||
Medical condition: Idiopathic Membranous Glomerulonephropathy (IMGN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001923-30 | Sponsor Protocol Number: TN-20 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:TRIALNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA | |||||||||||||
Full Title: Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001034-11 | Sponsor Protocol Number: CLOU064A2303B | Start Date*: 2022-11-25 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerabili... | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SK (Ongoing) DE (Ongoing) AT (Completed) HU (Ongoing) IT (Ongoing) BG (Ongoing) DK (Ongoing) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000241-21 | Sponsor Protocol Number: BEL114870 | Start Date*: 2011-06-23 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients | |||||||||||||
Medical condition: Chronic Immune Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001621-29 | Sponsor Protocol Number: 80804002 | Start Date*: 2009-05-05 |
Sponsor Name:Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden | ||
Full Title: Pre-POINT (Primary Oral INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for ty... | ||
Medical condition: pre-type 1 diabetes (islet autoimmunity in non-diabetic relatives of subjects with type 1 diabetes) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001586-87 | Sponsor Protocol Number: RSLV-132-04 | Start Date*: 2016-09-29 |
Sponsor Name:Resolve Therapeutics, LLC | ||
Full Title: A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome | ||
Medical condition: Primary Sjogrens Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005287-15 | Sponsor Protocol Number: 808040017 | Start Date*: 2015-07-15 |
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||
Full Title: - PRE-POINT-EARLY STUDY - Pilot study using oral insulin at early age for immune efficacy in primary prevention of type 1 diabetes | ||
Medical condition: Risk for type 1 diabetes | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007484-16 | Sponsor Protocol Number: DIAPREV/2008 | Start Date*: 2009-02-27 |
Sponsor Name:Helena Elding Larsson | ||
Full Title: DIAPREV-IT Diabetes Prevention Immune Tolerance. A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in ... | ||
Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003379-31 | Sponsor Protocol Number: 808040015 | Start Date*: 2017-01-31 |
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||
Full Title: An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes | ||
Medical condition: Risk for type 1 diabetes | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004374-27 | Sponsor Protocol Number: ProPATIent | Start Date*: 2006-10-12 |
Sponsor Name:Philipps-University | ||
Full Title: Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent) | ||
Medical condition: Generalized Myasthenia gravis with positive antibodies against Acetylcholine-receptors (ICD10GM2006 G70.0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-003028-30 | Sponsor Protocol Number: 808040019 | Start Date*: 2015-11-02 |
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||
Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes | ||
Medical condition: Risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005732-29 | Sponsor Protocol Number: MOM-M281-011 | Start Date*: 2021-11-19 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generali... | |||||||||||||
Medical condition: Myasthenia gravis (MG). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002269-77 | Sponsor Protocol Number: IM101611 | Start Date*: 2017-08-07 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in ... | |||||||||||||
Medical condition: Idiopathic Inflammatory Myopathy (IIM; eg, Dermatomyositis [DM], Polymyositis [PM], autoimmune necrotizing myopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000634-39 | Sponsor Protocol Number: 808040006 | Start Date*: 2007-09-03 |
Sponsor Name:Forschergruppe Diabetes e. V. am Helmholtz Zentrum München | ||
Full Title: Postpartum Intervention in Women with Gestational Diabetes using Insulin | ||
Medical condition: women with a recent history of gestational diabetes which required insulin therapy up to 7 months post-partum | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001852-41 | Sponsor Protocol Number: GLP1-FMT | Start Date*: 2022-09-06 |
Sponsor Name:Radboud university medical center | ||
Full Title: BetaFIT study: Beta cell imaging after Faecal mIcrobiota Transplantation | ||
Medical condition: Type 1 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002261-19 | Sponsor Protocol Number: PRN1008-012 | Start Date*: 2018-12-12 | ||||||||||||||||
Sponsor Name:Principia Biopharma | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus | ||||||||||||||||||
Medical condition: pemphigus vulgaris [PV] or pemphigus foliaceus [PF] | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) GR (Completed) HR (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005667-25 | Sponsor Protocol Number: HGS1006-C1113 | Start Date*: 2013-01-22 | |||||||||||
Sponsor Name:GlaxoSmithKline, LLC | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | |||||||||||||
Medical condition: Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) ES (Completed) IT (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003520-20 | Sponsor Protocol Number: R668-BP-1902 | Start Date*: 2020-05-19 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | |||||||||||||
Medical condition: Bullous pemphigoid (BP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) PL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003755-64 | Sponsor Protocol Number: DiAPREV/2014 | Start Date*: 2014-11-13 |
Sponsor Name:Helena Elding Larsson | ||
Full Title: A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® in combination with Vitamin D on the progression to type 1 diabetes in children with multip... | ||
Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000424-35 | Sponsor Protocol Number: CLOU064A2302 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urt... | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) DE (Ongoing) DK (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.